Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Fulgent Genetics, Inc.NASDAQ: FLGT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $39.91M rose 18.2% year over year, behind the +30.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 24.2% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Selling, general & admin amounted to 49.6% of revenue in FY2025, up 5.7 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of $114.19M (-28.6%) for the fiscal year ending Dec 2026, a slowdown from the +28.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $39.91M-24.2% QoQ
- Last fiscal yearDec 2025
- $160.04M+28.7% YoY
- LTMMar 2026
- $166.18M+30.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 160.04M USD
- Year-over-year change
- +28.7%
- 4-year CAGR
- +20.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 160.04M | +28.7% |
| FY2024 | 2024-12-31 | 124.35M | -4.7% |
| FY2023 | 2023-12-31 | 130.47M | -13.0% |
| FY2022 | 2022-12-31 | 149.99M | +99.5% |
| FY2021 | 2021-12-31 | 75.17M | — |
Selling, General & Admin vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 selling, general & admin of $166.18M is the 7th highest of the 8 companies compared; the peer median is $359.09M.
- Its year-over-year change of +30.2% is the 4th highest of 8, against a peer median of +26.4%.
- Selling, general & admin amounts to 51.9% of revenue for FLGT, versus a peer median of 64.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.25B | +22.3% | +26.0% | 46.4% | |
| LTM Sep 2026 | $951.07M | +44.5% | +15.0% | 74.4% | |
| LTM Mar 2026 | $537.7M | -3.2% | +1.5% | 64.9% | |
| LTM Jun 2026 | $359.09M | +0.6% | +9.5% | 46.9% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $292.26M | +58.0% | -10.9% | 64.3% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $180.71M | +60.0% | — | 45.5% |
| LTM Mar 2026 | $166.18M | +30.2% | +2.2% | 51.9% | |
| LTM Mar 2026 | $59.21M | +26.4% | -5.7% | 91.8% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | $359.09M | +26.4% | +5.5% | 64.3% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Cost of Revenue | 215.53M | 252.07M | 184.76M | 176.26M | 191.8M |
| Gross Profit | 777.05M | 366.9M | 104.46M | 107.22M | 130.88M |
| Gross Margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Research & Development | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Selling, General & Admin | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Operating Expenses | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| EBITDA | 692.04M | 217.7M | (147.45M) | (26.86M) | (45.83M) |
| EBITDA Margin | 69.7% | 35.2% | -51.0% | -9.5% | -14.2% |
| Operating Income | 675.95M | 178.53M | (195.53M) | (73.92M) | (91.1M) |
| Operating Margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Interest Income | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
| Interest Expense | 0 | 1.01M | 488K | 170K | 75K |
| Other Income / Expenses | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
| Income Before Tax | 681.03M | 184.03M | (174.09M) | (51.96M) | (70.03M) |
| Pre-Tax Margin | 68.6% | 29.7% | -60.2% | -18.3% | -21.7% |
| Income Tax Expense | 174.8M | 42.1M | 1.15M | (8.14M) | (8.39M) |
| Net Income | 507.36M | 143.4M | (167.83M) | (42.71M) | (60.51M) |
| Net Margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (Basic) | 17.13 | 4.76 | (5.63) | (1.41) | (1.97) |
| EPS (Diluted) | 16.26 | 4.63 | (5.63) | (1.41) | (1.97) |
| Weighted Avg Shares | 29.41M | 30.1M | 29.78M | 30.24M | 30.78M |
| Weighted Avg Shares (Diluted) | 30.98M | 30.96M | 29.78M | 30.24M | 30.78M |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.